

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/834,424
				Filing Date	April 13, 2001
				First Named Inventor	Stuart L. Schreiber
				Art Unit	1636
				Examiner Name	Nancy T. Vogel
Sheet	1	of	2	Attorney Docket Number	2003028-0048

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		7037902-B2	May 2, 2006	Olsson <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	B1	WO-9418317	08-18-1994	The Board of Trustees of the Leland Stanford Junion University; President and Fellows of Harvard College		
	B2	WO-0780325	07-19-2007	Sanofi-Aventis		
	B3	WO-9741526	11-06-1997	The Scripps Research Institute		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Austin <i>et al.</i> , Chem. Biol., 1:131-136, 1994.	
	C27	Barleon <i>et al.</i> , J. of Biol. Chem., 272(16):10382-10388, 1997.	
	C2	Bazan Proc. Natl. Acad. Sci., 87:6934-6938, 1990.	
	C28	Bunin <i>et al.</i> , J. Am. Chem. Soc., 114:10997-10998, 1992.	
	C3	Burch <i>et al.</i> , Pharm. Res., 8(2):141-147, 1991.	
	C4	Cochet <i>et al.</i> , J. of Biol. Chem., 263(7):3290-3295, 1988.	
	C5	Connolly <i>et al.</i> , Bioorganic & Medicinal Chemistry Letters, 10:1995-1999, 2000.	
	C6	DeWitt <i>et al.</i> , Proc. Natl. Acad. Sci. USA., 90:6909-6913, 1993.	
	C29	Doyle <i>et al.</i> , J. of Biol. Chem., 278(11):9426-9434, 2003	
	C7	Duquesnoy <i>et al.</i> , EMBO Journal, 13(6):1386-1395, 1994.	
	C30	European Patent Office: Decision revoking European patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated February 9, 2009.	
	C31	European Patent Office: Information about the result of oral proceedings for patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated December 10, 2008	
	C32	European Patent Office: Minutes of oral proceedings for patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated February 6, 2009.	
	C33	European Patent Office: Summons to attend oral proceedings in connection with patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated May 27, 2008	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/834,424
				Filing Date	April 13, 2001
				First Named Inventor	Stuart L. Schreiber
				Art Unit	1636
				Examiner Name	Nancy T. Vogel
Sheet	2	of	2	Attorney Docket Number	2003028-0048

	C8	Frank <i>et al.</i> , Endocrinology, 135(1):148-156, 1994.	
	C34	Goldberg <i>et al.</i> , J. Am. Chem. Soc. 124(4):544-555, 2002.	
	C9	Gordon <i>et al.</i> , J. of Med. Chem., 37(10):1385-1401, 1994.	
	C10	Greenlund <i>et al.</i> , J. of Biol. Chem., 268(24):18103-18110, 1993.	
	C11	Heidaran <i>et al.</i> , J. of Biol Chem., 266(30):20232-20237, 1991.	
	C12	Ibanez, EMBO Journal, 12(6):2281-2293, 1993.	
	C13	Ji, Methods in Enzymology, 91:580-609, 1983.	
	C35	Johnson <i>et al.</i> , Nephrol. Dial. Transplant., 15: 1274-1277, 2000.	
	C36	Kaushansky, Leukemia, 15:673-674, 2001.	
	C14	Kubar <i>et al.</i> , Biochemistry, 28:1086-1093, 1989.	
	C15	Letter from Sanofi-Aventis S.A. opposing patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated December 20, 2007.	
	C16	Letter from Sanofi-Aventis S.A. opposing patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated July 24, 2006.	
	C17	Letter from Carpmaels & Ransford on behalf of Ariad Gene Therapeutics, Inc. regarding opposition to patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated August 2, 2007.	
	C37	Letter from Sanofi-Aventis S.A. opposing patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated December 20, 2007 (Translation)	X
	C38	Letter from Sanofi-Aventis S.A. opposing patent EP0787207 in the name of Ariad Gene Therapeutics, Inc. dated October 10, 2008	
	C18	Qureshi <i>et al.</i> , Proc. Natl. Acad. Sci., 96(21):12156-12161, 1999.	
	C19	Rui <i>et al.</i> , Endocrinology, 135(4):1299-1306, 1994.	
	C39	Savi <i>et al.</i> , Proc. Natl. Acad. Sci. 103(29):11069-11074, 2006.	
	C20	Seed, Chem. Biol., 1:125-129, 1994.	
	C21	Spencer <i>et al.</i> , Science, 262:1019-1024, 1993.	
	C22	Tian <i>et al.</i> , Science, 281:257-259, 1998.	
	C23	Watowich <i>et al.</i> , Mol. and Cell. Biol., 14(6):3535-3549, 1994.	
	C24	Watowich <i>et al.</i> , Proc. Natl. Acad. Sci. USA, 89:2140-2144, 1992.	
	C25	Wells, Curr. Opin. Cell Biol., 6:163-173, 1994.	
	C26	Wold, Methods in Enzymology, 11:617-640, 1966.	
	C40	Written Opinion of the ISA/EP for PCT/2007/000051 (published as WO-0780325) dated September 9, 2008.	X

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.